Clinical Trial Update: Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sonidegib and lenalidomide after stem cell transplant in patients with recurrent or refractory multiple myeloma has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Sonidegib (Sonidegib)

Snippet

Sponsor: Mayo Clinic | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2019-05-29